In BC, DAB2IP inhibited epithelial‐to‐mesenchymal transition (EMT), a critical regulator of the CSC phenotype,21 while DAB2IP modulates CSC capacity, and chemoresistance has not been examined in BC. Here, DAB2IP is linked to breast cancer.